Impact of timing of immunotherapy and cytoreductive nephrectomy in metastatic renal cell carcinoma: Real-world data on survival outcomes from the CKCis database

The primary objective of this study was to assess outcomes in patients who received only immunotherapy-based systemic treatment (ST), the standard of care for most patients diagnosed with metastatic renal cell carcinoma (mRCC), vs. those who received cytoreductive nephrectomy (CN) followed by ST (CN-ST), and ST followed by CN (ST-CN). Researchers queried the Canadian Kidney Cancer information system database to identify patients with de novo mRCC who received immunotherapy-based ST between January 2014 and June 2023.